CStone Pharmaceuticals (HKG:2616) intends to buy back up to nearly 136.5 million shares from the open market from time to time under a mandate approved June 25, 2025, according to a Wednesday Hong Kong bourse filing.
The repurchase plan is expected to be implemented following the American Society of Clinical Oncology (ASCO) Annual Meeting.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.